Drug Discovery & Pharmaceuticals

RSS

Promega unveils cellular target engagement technology aimed at expanding the druggable proteome at SLAS 2026

Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins.

From Promega Corporation 27 Feb 2026

New daily tablet simplifies long-term HIV care

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), may be able to effectively replace more complicated HIV treatment regimens used by people living with HIV who are long-term survivors, according to the results of a new phase 3 clinical trial published in The Lancet.

26 Feb 2026

Automated platform finds unexpected enhancers for mRNA therapeutics

Integrating AI with advanced robotics to create self-driving labs (SDL) is a promising approach to tackling molecular discovery.

24 Feb 2026

SwRI advances safer manufacturing of nerve agent antidotes

Southwest Research Institute (SwRI) continues to expand its unique drug synthesis capabilities and expertise to advance the scalable manufacturing of safer antidotes to combat exposure to organophosphorus nerve agents (OPNAs) and pesticides.

24 Feb 2026

Disordered lipid nanoparticles enhance RNA delivery efficiency

The tiny fatty capsules that delivered COVID-19 mRNA vaccines into billions of arms may work better when they're a little disorganized.

22 Feb 2026

New technique synthesizes non-natural amino acids for advanced peptide therapeutics

Ozempic has been making headlines for its remarkable success in treating obesity and diabetes. Yet it is just one in a rapidly growing class of drugs called peptide therapeutics that sits between small molecules (like aspirin) and biologics (like antibodies).

20 Feb 2026

Axol Bioscience acquires ophthalmology business from Newcells Biotech

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, today announced that it has acquired the ophthalmology business of Newcells Biotech (Newcells), a leading drug discovery partner specializing in the development of in vitro models and bespoke assay services.

18 Feb 2026

Insilico Medicine and MSK collaborate to discover new drug targets for gastroesophageal malignancies

Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaborative research agreement aimed at discovering new therapeutic targets for gastroesophageal malignancies.

17 Feb 2026

Harnessing AI to optimize the development of new protein manufacturing processes

Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful compounds.

17 Feb 2026

Calibr-Skaggs and Kainomyx join forces to accelerate development of antimalarial drugs

The Calibr-Skaggs Institute for Innovative Medicines at Scripps Research and Kainomyx, Inc., today announced a new research collaboration to accelerate the discovery and development of next-generation antimalarial drugs.

17 Feb 2026

Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins

Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific partnership.

17 Feb 2026

Aptar Pharma’s intranasal solutions power CastleVax Phase II clinical trials for next-gen COVID-19 vaccine

In a significant step forward for mucosal immunity, Aptar Pharma has announced that its innovative nasal delivery systems are being utilized in CastleVax’s Phase II clinical trial for CVAX-01, an intranasal COVID-19 vaccine candidate.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 16 Feb 2026

New AI framework enables reliable intracellular antibody design

A new artificial intelligence-driven pipeline developed in a collaborative research combines protein structure prediction, sequence design, and live-cell screening together to enable rapid conversion of antibody sequences into functional intracellular antibodies (intrabodies) that are stable within living cells.

13 Feb 2026

Tahoe Therapeutics generates the largest single-cell atlas ever using INTEGRA Biosciences automated pipetting technologies

Tahoe Therapeutics - a biotech start-up based in San Francisco, California - is creating the largest ever atlas of cell-chemical interactions to inform drug discovery. Combining automated pipetting systems from INTEGRA Biosciences, Parse Biosciences' Evercode™ single-cell RNA sequencing (scRNA-seq) products, and its own proprietary AI algorithms, the company already has several drug discovery programs running in parallel across multiple cancer types, and is expanding into other therapeutic areas.

12 Feb 2026

SPT Labtech and Bellbrook Labs introduce high-throughput screening platform for cancer research

SPT Labtech, a global leader in the design and development of automated instrumentation and consumables for life sciences, and BellBrook Labs, a pioneer in high-throughput screening (HTS) assay tools, today announced a collaboration to advance cancer research.

9 Feb 2026

Synthace collaborates with Charles River to offer the global pharma industry more robust, faster and cost-effective assays

Synthace, the leader in software and services for assay development, today announced a collaboration with Charles River Laboratories International, Inc. (Charles River), a leading global drug discovery, development, testing, and manufacturing solutions provider.

9 Feb 2026

Drug Discovery & Pharmaceuticals

Promega unveils cellular target engagement technology aimed at expanding the druggable proteome at SLAS 2026

New daily tablet simplifies long-term HIV care

Automated platform finds unexpected enhancers for mRNA therapeutics

SwRI advances safer manufacturing of nerve agent antidotes

Disordered lipid nanoparticles enhance RNA delivery efficiency

New technique synthesizes non-natural amino acids for advanced peptide therapeutics

Axol Bioscience acquires ophthalmology business from Newcells Biotech

Insilico Medicine and MSK collaborate to discover new drug targets for gastroesophageal malignancies

Harnessing AI to optimize the development of new protein manufacturing processes

Calibr-Skaggs and Kainomyx join forces to accelerate development of antimalarial drugs

Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins

Aptar Pharma’s intranasal solutions power CastleVax Phase II clinical trials for next-gen COVID-19 vaccine

New AI framework enables reliable intracellular antibody design

Tahoe Therapeutics generates the largest single-cell atlas ever using INTEGRA Biosciences automated pipetting technologies

SPT Labtech and Bellbrook Labs introduce high-throughput screening platform for cancer research

Synthace collaborates with Charles River to offer the global pharma industry more robust, faster and cost-effective assays

AI model accelerates antibody production and clone selection

Tumor-targeted chimeric drug increases efficacy and limits side effects

Revvity unveils new high-impact discovery platforms and showcases recent innovations at SLAS2026

New platform improves prediction of human antibody drug responses

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest Life Science News